



Joyce O'Shaughnessy

Kontakt

Joyce O'Shaughnessy

Publikationen (10)

Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolane S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. *Ann Oncol* 2024

Goetz M, Cicin I, Testa L, Tolane S, Huober J, Guarneri V, Johnston S, Martín M, Rastogi P, Harbeck N, Shahir A, Wei R, Andre V, Rugo H, O'Shaughnessy J. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. *NPJ Breast Cancer* 2024; 10:34.

Rastogi P, O'Shaughnessy J, Martín M, Boyle F, Cortes J, Rugo H, Goetz M, Hamilton E, Huang C, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andre V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. *J Clin Oncol* 2024:JCO2301994.

Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang C, Huober J, Jaliffe G, Cicin I, Tolane S, Goetz M, Rugo H, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol* 2022

Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. *NPJ Breast Cancer* 2021; 7:142.

Johnston S, Harbeck M, Martin H, Andre V, Sohn J, Toi M, Huober J, Martín M, O'Shaughnessy J, Goetz M. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. *NPJ Breast Cancer* 2021; 7:80.

Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrightNess Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7:603-608.

Johnston S, Huober J, Wardley A, Tolane S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). *J Clin Oncol* 2020; 38:3987-3998.

Golshan M, Sikov W, Geyer C, von Minckwitz G, Metzger-Filho O, Sullivan D, Maag D, Ansell P, Wolmark N, Rugo H, O'Shaughnessy J, Huober J, Loibl S, Wong S, Untch M. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrightNess trial. *Eur J Surg Oncol* 2019; 46:223-228.

Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrightNess): a randomised, phase 3 trial. *Lancet Oncol* 2018; 19:497-509.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch